What Is Belkyra™?
Belkyra™ is the first and only FDA and Health Canada approved injectable drug that contours and improves the appearance of submental fullness due to submental fat, sometimes referred to as a double chin.
Submental fullness is a common, yet undertreated, facial aesthetic condition which can detract from an otherwise balanced facial appearance and lead to an older and heavier look.
In the United States Belkyra™ is marketed under the trade name Kybella™. Canada and the US are currently the only countries in the world where Belkyra non-surgical injectable treatments are available, and Dermetics is one of the first clinics to offer Belkyra™ treatments to our patients.
How Belkyra™ Works
Belkyra™ is a formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids the breakdown and absorption of dietary fat. When injected into subcutaneous fat, Belkyra™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Dr. Muhn and Dr. Rosen customize treatments to each patient’s aesthetic goals for an improved chin profile and administer Belkyra™ injectables into the fat under the chin. Local anaesthetic is used to ensure patient comfort.
Each in-office treatment takes approximately 30 minutes. Patients typically require two to four treatments a minimum of four weeks apart.
Common side effects may include swelling, bruising, pain, numbness, redness or formation of small areas of firmness. Less common potential side effects include temporary nerve injury, trouble swallowing, skin ulceration and hair loss at treatment site. All reported side effects are temporary and resolved without treatment. Results are considered permanent once the desired outcome has been achieved.